A basic insight into COVID-19 vaccines: an overview

Authors

  • Sarfaraz Alam Khan Department of Pharmacology, Chhindwara Institute of Medical Sciences, Chhindwara, Madhya Pradesh, India
  • Nazeem Ishrat Siddiqui Department of Physiology, Government Medical College, Khandwa, Madhya Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20231903

Keywords:

COVID-19, COVID-19 vaccine, SARS-CoV-19

Abstract

Atypical serious respiratory illnesses were reported in December 2019 from Wuhan, a city of China, which later spread to other places rapidly and became a global pandemic. Soon it was discovered to be caused by a novel corona virus, named as the severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) and the disease caused by it as corona virus disease-19 (COVID-19). Since COVID-19 is a new viral disease, world is still struggling to find out a permanent remedy to overcome this serious health problem. Developing safe and effective vaccine against SARS-CoV-2 has become the only way forward to tackle it. Various vaccines have been developed and are approved for mass vaccination on emergency basis. Both classical and next generation vaccine platforms are being used to develop COVID-19 vaccine. It seems interesting to have a look on the various types of vaccines and get an insight into them so that we can get familiarize with the COVID-19 vaccination.

References

Awadasseid A, Wu Y, Tanaka Y, Zhang W. Initial success in the identification and management of the coronavirus disease 2019 (COVID-19) indicates human-to-human transmission in Wuhan, China. Int J Biol Sci. 2020;16:1846-60.

HuiDS IAE, Madani T, Ntoumi F, Koch R, Dar O. The continuing 2019-nCoV Epidemic threat of novel coronaviruses to global health: the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264-6.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.

Control ECfDPa. European Centre for Disease Prevention and Control. 2020. Available at: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases. Accessed on 12 February 2023.

Zeidler A, Karpiński TM. SARS-CoV, MERS-CoV, SARS-CoV-2 comparison of three emerging Coronaviruses. Jundishapur J Microbiol. 2020;13:e103744.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-74.

Zhang J, Zeng H, Gu J, Li H, Zheng L, Zou Q. Progress and prospects on vaccine development against SARS-CoV-2. Vaccines. 2020;8:153.

Funk CD, Laferrière C, Ardakani A. A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic. Front Pharmacol. 2020;11:937.

Mahmood Z, Alrefai H, Hetta HF, A Kader H, Munawar N, Abdul Rahman S, et al. Investigating Virological, Immunological, and Pathological Avenues to Identify Potential Targets for Developing COVID-19 Treatment and Prevention Strategies. Vaccines (Basel). 2020;8(3):443.

Datta PK, Liu F, Fischer T, Rappaport J, Qin X. SARS-CoV-2 pandemic and research gaps: understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics. 2020;10:7448-64.

Cyranoski D. Profile of a killer: the complex biology powering the coronavirus pandemic. Nature. 2020;581:22-6.

Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020;78:779-84.

Funk CD, Laferrière C, Ardakani A. A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic. Front Pharmacol. 2020;11.

McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses. 2014;6:2991-3018.

Satarker S, Nampoothiri M. Structural proteins in Severe Acute Respiratory Syndrome Coronavirus-2. Arch Med Res. 2020;51:482-91.

Siu YL, Teoh KT, Lo J, Chan CM, Kien F, Escriou N, et al. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J Virol. 2008;82:11318-30.

Verdiá-Báguena C, Nieto-Torres JL, Alcaraz A, DeDiego ML, Torres J, Aquilella VM, et al. Coronavirus E protein forms ion channels with functionally and structurally-involved membrane lipids. Virology. 2012;432:485-94.

Yoshimoto FK. The proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19. Protein J. 2020;39:198-216.

Bartsch SM, O'Shea KJ, Ferguson MC, Bottazzi ME, Wedlock PT, Strych U, et al. Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention. Am J Prev Med. 2020;59(4):493-503.

Rajão DS, Pérez DR. Universal vaccines and vaccine platforms to protect against influenza viruses in humans and agriculture. Front Microbiol. 2018;9:123.

Soema PC, Kompier R, Amorij J-P, Kersten GFA. Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm. 2015;94:251-63.

van Riel D, de Wit E. Next-generation vaccine platforms for COVID-19. Nat Mater. 2020;19:810-2.

Liu X, Liu C, Liu G, Luo W, Xia N. COVID-19: Progress in diagnostics, therapy and vaccination. Theranostics. 2020;10:7821-35.

Karpiński TM, Ożarowski M, Seremak-Mrozikiewicz A, Wolski H, Wlodkowic D. The 2020 race towards SARS-CoV-2 specific vaccines. Theranostics. 2021;11(4):1690-702.

Wang J, Peng Y, Xu H, Cui Z, Williams RO. The C OVID-19 vaccine race: challenges and opportunities in vaccine formulation. AAPS Pharm Sci Tech. 2020;21:225.

World Health Organization. Draft landscape of COVID-19 candidate vaccines. Available at: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed on 16 February 2023.

Wang J, Peng Y, Xu H, Cui Z, Williams RO. The C OVID-19 vaccine race: challenges and opportunities in vaccine formulation. AAPS Pharm Sci Tech. 2020;21:225.

World Health Organization. Available at: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_02April2022.pdf. Accessed on 16 February 2023.

Pillet S, Aubin É, Trépanier S, Bussiere D, Dargis M, Poulin JF, et al. A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. Clin Immunol Orlando Fla. 2016;168:72-87.

Daniell H, Singh ND, Mason H, Streatfield SJ. Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci. 2009;14:669-79.

Zeltins A. Construction and characterization of virus-like particles: a review. Mol Biotechnol. 2013;53:92-107.

Jain S, Venkataraman A, Wechsler ME, Peppas NA. Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Adv Drug Deliv Rev. 2021;179:114000.

Liu MA. A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines. 2019;7:337.

Mallapaty S. India’s DNA COVID vaccine is a world first – more are coming. Available at: www.nature.com/articles/d41586-021-02385-x. Accessed on 16 February 2023.

South Africa may swap or sell AstraZeneca's Covid-19 vaccine. Available at: www.bbc.com/news/world-africa-56009170. Accessed on 16 February 2023.

Downloads

Published

2023-06-27

How to Cite

Khan, S. A., & Siddiqui, N. I. (2023). A basic insight into COVID-19 vaccines: an overview. International Journal of Basic & Clinical Pharmacology, 12(4), 626–630. https://doi.org/10.18203/2319-2003.ijbcp20231903

Issue

Section

Review Articles